-
Novel Psychoactive Substances: What is Xylazine?
Substance use can take many forms and often involves many unknowns. One of the most important aspects of illicit substance use, especially for the end…
-
Medication Monitoring in a Changing Opioid Prescribing Landscape
The new 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain is an update to the most recent practice guideline published in 2016.1,2…
-
Aegis's Novel Psychoactive Substance (NPS) Testing Menu Update
In September, Aegis updated both urine and oral fluid novel psychoactive substance (NPS) test menus as a continued commitment to offering providers a contemporary…
-
InterACT Rx Pharmacodynamic Insights: A Brief Look at QTc Prolongation, Serotonin Syndrome, and Tardive Dyskinesia
Introduction Some combinations of medications can lead to serious pharmacodynamic interactions with clinical effects that can be life-threatening in some…
-
Complexities of Risk Assessment: Opioids, Drug Interactions, & Designer Benzodiazepines
As the number of fatal and non-fatal overdoses continues to rise, we should question why this is occurring. One frequent cause of death in drug overdose…
-
Behavioral Health: Why Monitor Patients for Medication Adherence?
Mental health illness affects almost a half billion people globally every year including millions of Americans. Data from 2020 showed that 21% of Americans…
-
Novel Psychoactive Substances (NPS): What's New in 2022
Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit drugs. There are various…